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INTRODUCTION 
Perimenopausal bleeding is one of the commonest conditions for 
which patients seek advice in the gynaecological outpatient department. 
The prevalence increases with age, peaking just prior to menopause. 
Because most cases are associated with anovulatory menstrual cycles, 
perimenopausal women are particularly vulnerable. Throughout the 
perimenopausal transition, there is a significant incidence of DUB due to 
anovulation1. Perimenopause is the period 2-8 years preceding the  
menopause and 1 year after  final menses (WHO).However a better  
definition is the phase preceeding the onset of menopause, occurring 
around  the age of 40-50 years  (beginning at age 47.5, lasting for 4 years) 
during which the regular menstrual cycle of a woman transitions to a 
pattern of irregular cycles.2 
Perimenopausal bleeding refers to the symptoms of excessive, 
unexpected, prolonged, or acyclic bleeding, regardless of the  diagnosis 
or cause 3.With medical advancements and the  increasing awareness 
about gynaecological problems, most women gain access to most of the 
diagnostic and therapeutic modalities. Endometrial biopsy is relatively 
simple, accurate and inexpensive. The only disadvantage of the  
endometrial biopsy is that, it is an invasive procedure. The main  reason 
for obtaining endometrial histology in perimenopausal patients with 
bleeding  is to exclude the presence of endometrial hyperplasia or 
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carcinoma of endometrium4. Both typical hyperplasia and atypical 
hyperplasia  may regress spontaneously over months or  few years. 
However, atypical  hyperplasia  is a precancerous condition that may 
progress to  malignancy and best treated by surgery with hysterectomy. 
Hyperplasia without atypia    regresses  spontaneously after D&C or 
progestin treatment. In patients with atypical hyperplasia, if conserving 
the uterus is considered, a trial of hormonal treatment may be given. 
Analysis of  steroid hormone receptors  play  an important role  in 
patients with perimenopausal bleeding  to predict the response  to 
hormonal therapy4. Currently, the steroid hormone receptor status of 
carcinoma of the endometrium has been demonstrated to be 
prognostically important.  
In this  study  of  200 cases an attempt is made to evaluate the 
histomorphological profile of endometrium in perimenopausal bleeding, 
and the immunohistochemical expression of  ER  and PR in endometrial 
hyperplasias.  
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AIMS AND OBJECTIVES 
1. To evaluate the incidence of perimenopausal bleeding in our 
institution. 
2. To identify the distribution of cases among various age groups.  
3. Analysing the histomorphological pattern of endometrium in 
perimenopausal  bleeding. 
4. To evaluate the expression of ER and PR in endometrial hyperplasias 
by immunohistochemical method. 
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REVIEW OF LITERATURE 
"The term "menstruation" arose  from "menstruus" a latin word 
meaning "monthly". The  literature on  the etiology of   uterine bleeding 
disorders  dates back to 1846-53, when French surgeon Robert (1846) 
Robin and Nelatan (1853) observed  that hyperplasia of the endometrium, 
is one of the common cause5. 
 
 
 
 
 
 
 
Figure 1: Schematic representation of the female genital tract. 
PHYSIOLOGY OF MENSTRUATION: 
As perimenopausal bleeding  is a hormonal disorder, knowledge of 
the normal hormonal control mechanism  of menstruation is useful.  
The Phenomena of Menstruation: 
Menstruation is defined as a 'periodic and cyclical shedding of  the 
progestational endometrium accompanied by the loss of  blood' during 
the reproductive age between menarche and menopause6,7. The normal 
menstrual cycle occurs  approximately  at 28 day intervals with a range of 
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21 - 35 days, the flow lasting for  4 ± 2 days, and the average blood loss 
is 40 ± 20 ml. 
The menstrual cycle is under complex hormonal control and  the 
morphology of  endometrium  closely reflects the endocrine status and 
the interplay between ovarian hormones. The cyclical endocrine  activity 
of the ovary and the hypothalamic-pituitary axis determines the  phases of 
a normal menstrual cycle8. 
The normal human menstrual cycle can be divided into two 
segments9 
• The ovarian cycle 
• The uterine cycle 
The ovarian cycle is further divided into: 
 Follicular phase 
 Ovulation 
 Luteal phase 
 The uterine cycle is divided into proliferative and secretory 
phases. The  four major hormones that are involved in the control of 
menstrual cycle and  measured in peripheral blood are: 
 Follicular stimulating hormone (FSH) 
 Luteinizing hormone (LH) 
 Estrogen 
 Progesterone 
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Their secretion pattern is inter-related and it reflects the cyclic 
patterns of  hypothalamic activity. Starting at menarche, the uterus 
undergoes monthly cyclic changes caused by differential production and 
secretion of the ovarian hormones, estrogen and progesterone (Fig. 2). 
OVARIAN CYCLE
 
Figure 2 : Changes in the endometrium in relation to the changes in 
the ovarian cycle. 
1. The follicular phase: 
During the follicular phase,a  sequence  of events takes place as a 
result of which mature follicles are produced.This process in which the 
follicle  matures  through the stages of  primordial follicle to  the stages 
of  preantral, antral, and preovulatory follicles10  requires a coordinated   
action of hormones on the  ovarian follicles.This  occurs over a span of 
10-14 days. Variations  in length of follicular phase is the cause  for most 
of the variations in total cycle length.  
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2. Ovulation: 
The preovulatory follicle, provides its own ovulatory stimulus 
through the secretion of estradiol. Even in the same woman,the timing of  
ovulation varies from cycle to cycle. It is  estimated that the  time of 
ovulation is  10-12 hours after the peak level of LH and 24-36 hours after 
the  peak estradiol levels. 34-36 hours prior to rupture of the ovarian 
follicle, the  LH surge  occurs and it is the  most reliable indicator of  
ovulation. Maintenance of LH concentration for a threshold period of  14-
27 hours helps in  full maturation of  the oocyte. LH surge usually lasts 
for 48-50 hours.  
3. Luteal phase: 
Before follicular rupture and the extrusion of the ovum, the 
granulosa cells begin to increase in size and has a characteristic 
vacuolated appearance. This is associated with the formation of  the 
corpus luteum, which has a characteristic yellow colour due to the 
deposition of  yellow pigment, lutein, which derives  its name from the 
process of  luteinization. The duration from ovulation to the menstrual 
onset constitutes the luteal phase , with an average length of 14 days.  
UTERINE CYCLE:    
The mucosal lining of the uterus, the endometrium, is composed of 
the glands and the stroma. The endometrium is composed of two layers.9 
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The Functionalis:  
This is the superficial two thirds of the endometrium that 
proliferates and is shed with each menstrual cycle if pregnancy does not 
occur. The functionalis may be differentiated into superficial compacta 
and the underlying spongiosa, in the second half of the menstrual cycle. 
The basalis:  
This is the deepest layer of the endometrium which does not 
undergo cyclical changes observed in the functional layer. This basal 
layer persists after menstruation and regenerates the functional layer. 
The endometrium varies in thickness throughout the cycles11. 
 At menstruation - 0.5mm thick 
 Immediate post menstrual phase -1-2mm thick 
 Proliferative phase - 2- 4mm thick 
 Mid secretory phase - 7-8mm thick 
There is some reduction of 5-6mm in the thickness of endometrium 
in the immediate premenstrual   phase. 
PHASES OF MENSTRUAL CYCLE: 
The normal menstrual cycle is divided into two main phases. 
1. The proliferative phase. 
2. The secretory phase. 
Estrogen predominates in the proliferative phase, and the 
progesterone action predominates in the secretory phase.  
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1. THE PROLIFERATIVE PHASE:  
This phase generally lasts two weeks but may fluctuate between 
one to twenty days. This phase is further subdivided into early, middle 
and late proliferative phases 9,12. 
a) The early proliferative phase:  
This phase occurs between fourth to seventh day of a twenty eight 
day cycle. The glands are sparse, narrow and straight with a  low 
columunar epithelial lining. Their nuclei are small, oval and the 
chromatin dense. Nucleoli are inapparent. There is evidence of mitotic 
activity both in the glands and the stroma, and the stroma remains dense 
in appearance. As the effect of estrogen steadily increases, the 
endometrium gradually shifts to the mid proliferative phase.  
b) Mid proliferative phase:  
This phase occurs between eight to tenth day of a twenty eight day 
cycle and the characteristic change in this stage is increase in the height 
of the endometrium due to stromal edema induced by estrogen. The 
glands become tortuous and elongated. Their epithelial cells become tall 
columnar with large, oval nuclei and dense chromatin. Nucleoli are 
apparent and many cells show mitosis. The stroma is made up of spindle 
shaped cells with scanty cytoplasm and large fusiform nuclei, separated 
by interstitial edema.  
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c) Late proliferative phase:  
This phase occurs between eleventh to fourteenth day of a twenty 
eight day cycle. The stromal edema subsides, the tortuosity of the glands 
are increased, and their lining epithelial cells show a pseudo stratified 
appearance. The nuclei are large with prominent nucleoli. At this time 
tiny granules of glycogen appear at the basal part of glandular cells. The 
granules stain red with Periodic acid Schiff stain. The stroma is compact 
with large and proliferated stromal cells with prominent nucleoli.  
2. THE SECRETORY PHASE: 
The normal secretory phase lasts approximately for fourteen days. 
Grossly, secretory endometrium is 3 to 5 mm thick and appears creamy 
yellow. At this phase, there is an overlap of both the proliferative and 
secretory activity, and the endometrial glands show both mitotic activity 
and secretory activity. This phase is divided into early secretory phase, 
mid secretory phase and late secretory phases 9,12. 
a) Early secretory phase:  
The appearance of the sub nuclear vacuolations is a characteristic 
feature of the early secretory phase. This phase lasts from the second 
postovulatory day to the fifth postovulatory day. The pseudo stratified 
appearance of the epithelium disappears and the glands become more 
tortuous.  
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b) Mid secretory phase:  
  This phase lasts from fifth day after ovulation till the eleventh day. 
The glands are irregular, in contrast to round or oval pattern seen in the 
proliferative phase. The luminal side of the glandular cells have secretory 
vacuoles. Apocrine secretions are seen in the cytoplasm in the luminal 
side of the cell. So the apical surface of the cells are rough and indistinct. 
The nuclei of epithelial cells are arranged in linear pattern and they are 
round and  vesicular. Stromal edema begins on the seventh day after 
ovulation and peaks at nine and ten days after ovulation. On ninth day 
after ovulation, groups of spiral arterioles become prominent, and they 
grow thicker, larger, and spirally twisted. 
Ten days after ovulation, the stromal edema starts to regress and 
stromal cells become decidualized. This change first appears as a 
solidification of the stromal cells around the spiral arterioles. The 
surrounding areas  have a loose edematous pattern. Eleven days after 
ovulation, the stromal edema decreases and decidual change of the 
stromal cells is more pronounced. The regression of the stromal edema is 
the result of decreasing levels of estradiol and progesterone, which in turn 
are the result of lysis of the corpus luteum. 
 c) Late secretory phase:  
This phase is characterized by compact stroma without edema. 
Decidual change and endometrial granulocytes are seen in the stroma of 
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superficial zone. Stroma in the spongy zone is undifferentiated. The 
glands have a characteristic 'saw toothed' appearance in the central zone, 
the spongy part of the endometrium. Epithelial cells are tall columnar 
with abundant secretions. The glands of stratum compactum are few in 
number and are lined by flattened cells. As the cycle ends, the stromal 
edema regresses completely and decidualization spreads throughout the 
endometrium.  
THE MENSTRUAL PHASE: 
If  pregnancy has not occurred, the late secretory phase enters to 
the menstrual phase which starts 14 days after ovulation. This phase is 
characterized histologically by crumbling of the stroma, glandular 
collapse and haemorrhage. On the second day of menstruation, scattered 
stromal cells and remnants of glandular epithelium are found admixed 
with fresh blood and aggregates of neutrophils 9. 
REGENERATION:  
Regeneration is in progress before the cessation of the menstrual 
flow and is complete by the time bleeding stops. The regeneration 
process starts in the glands retained in the basal layer and part of  
functional layer which are retained 9. 
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DEFINITION AND CLASSIFICATION OF DUB 
DUB is defined by various authors as follows: 
Sutherland (1949) 13 defined DUB as all forms of abnormal 
uterine bleeding (AUB) for which no detectable pathology and physical 
signs can be detected by clinical examination. Author divided DUB into,  
- Apparently normal endometrium 
- Irregular shedding 
- Irregular ripening of the endometrium 
- Endometrial atrophy 
- Endometrial hyperplasia 
DUB is defined by Vory and Neri (1967,1970)14,15   as AUB for 
which the cause cannot be detected  by history taking, physical 
examination, pelvic examination, pap smear and uterine curettage. They 
observed that,  DUB is caused not only by  anovulatory states, but also  
corpus luteum insufficiency, shortened cycles and classified DUB based 
on clinical features and etiology. 
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TABLE 1: CLASSIFICATION OF  DUB BASED ON CLINICAL 
FEATURES AND ETIOLOGY 
Type Cycle Type of bleeding Cause 
I. Ovulatory 
a) Follicular 
Abnormality 
a) Short proliferative 
phase  
Short cycles, normal 
bleeding. 
Hypersensitivity of 
ovary  
b)  Long 
proliferative 
Long cycle, normal 
bleeding 
Slow development of 
follicle. 
b)Corpus luteum 
Abnormality 
a) Insufficiency Premature spotting, 
short cycles 
Irregular ripening of 
endometrium 
b) Prolonged Prolonged cycle with 
 excessive 
bleeding 
Irregular shedding of 
 the endometrium 
II. Anovulatory a) Cyclic Normal cycle with 
excessive 
bleeding 
High peak estrogen 
level. 
Proliferative 
Endometrium 
 
b) Acyclic 
Irregular excessive 
bleeding 
 
 
Continuous high levels 
of estrogen, 
 Hyperplastic 
endometrium 
Irregular scanty 
bleeding 
Continuous low levels 
of estrogen, 
 Atrophic 
endometrium. 
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In 1981 Ackerman
16 
stated DUB as bleeding not associated with 
an organic cause in women of child bearing age. 
According to Kurman Robert J (1982)17 DUB is the term used for 
bleeding that is not due  to any underlying organic pathology and is 
therefore similar to  AUB, resulting  from  derangements in the amount  
or duration of estrogen and progesterone effects on the endometrium.  
According to Telinde (1997)18 DUB includes any condition of 
abnormal uterine bleeding in the absence of infection, pregnancy, 
neoplasm or other intra uterine lesions. He also observed that such 
bleeding is often the result of hormonal dysfunction that inhibits 
ovulation . 
Dutta in 200119 defined DUB as a state of abnormal uterine 
bleeding without any detectable organic pathology like inflammation, 
pregnancy or tumor. 
According to Jeffcoate (2002)20 all forms of abnormal uterine 
bleeding for which an organic pathology cannot be found, are grouped 
under DUB. 
He  classified DUB into, 
• Anovulatory DUB which is due to  absent corpus luteum. 
• Ovulatory DUB causing polymenorrhoea and polymenorrhagia  
• Corpus luteum defects. 
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Sherman Mark (2002)21 stated that DUB is a diagnosis of 
exclusion in which the uterine bleeding is not associated with any organic 
pathology.  
Shaws (2004)22 defined DUB as menorrhagia without any disease 
or  structural abnormality or diseases in the pelvis and with no other 
demonstrable extra genital cause for bleeding. He observed that the 
etiology is hormonal, due to increased levels of estrogen in the circulating 
blood which causes hyperplasia of the endometrium. 
PERIMENOPAUSE: 
In a study by Treloar, he observed that the average age for entry 
into the perimenopausal transition was 45.1, and the age range that 
included 95% of the women was 39–51years (Treloar AE, 1996). He also 
observed that the range of perimenopausal transition was 2 to 8 years, 
with a mean duration of 5 years23. 
WHO Scientific Group 1996 Research on the menopause states 
that “The term perimenopause   include  the period immediately before 
the menopause (when the biological, endocrinological, and clinical 
features of approaching menopause commence) and the first year after 
menopause24. 
Perimenopause is the period 2-8 year preceding menopause and 
one  year after the final menses (WHO).However a better  definition is, 
the phase preceding the onset of menopause, occurring around 40-50 
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years of age (beginning at age 47.5, lasting for 4 years) during which the 
regular cycle of a woman transitions to irregular cycles2. 
Joseph et al states that the term perimenopause, which literally 
means “about or around the menopause,” begins at the same time as the 
menopausal transition and ends one year after the final menstrual 
period25. 
Definition of Perimenopausal Bleeding: 
Perimenopausal bleeding refers to the symptoms of  prolonged, 
excessive, acyclic bleeding or unexpected bleeding , regardless of the 
diagnosis or cause26.Almost 90% of women will have four to eight years 
of menstrual cycle irregularities before menopause. It is important to 
differentiate irregular bleeding during the perimenopause from abnormal 
uterine bleeding (AUB). AUB is more common in  the perimenopausal 
years. AUB refers to the symptoms of prolonged,excessive, acyclic 
bleeding or unexpected bleeding , regardless of  the diagnosis or cause, 
whereas dysfunctional uterine bleeding (DUB) is a term which refers to  
any abnormal bleeding from an essentially normal uterus26. 
During the perimenopause, AUB is related to both altered 
hormonal function of  the ovaries and to uterine abnormalities.The 
perimenopause is characterized by increasing unpredictability and  
irregularity of menstrual cycles27. Physiologic changes include an 
increasing incidence of short and long follicular phases, anovulation, 
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defective ovulation, corpus luteum insufficiency and erratic cycles. Most 
often these changes are associated with premenstrual follicle stimulating 
hormone (FSH) increase. Throughout the perimenopausal transition, there 
is a significant increase in the incidence of  DUB due to anovulation28. 
Though uncommon in the perimenopausal age, the rate of 
endometrial neoplasia begins to increase sharply at age 40-5029. 
Perimenopausal bleeding may be a sign of atypical hyperplasia of 
endometrium, which if undiagnosed and untreated may progress to 
endometrial carcinoma28. Although changes in bleeding pattern in 
perimenopausal patients are normal, it is critical for clinicians to 
recognize abnormal bleeding patterns so that proper investigations can be 
carried out. 
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Causes of AUB in Perimenopausal Women26 
      TABLE 2: DIFFERENTIAL DIAGNOSIS OF ABNORMAL      
UTERINE BLEEDING IN PERIMENOPAUSAL WOMEN 
A Organic causes 
 Benign reproductive tract diseases 
Leiomyomata uteri  
Polyps  
Adenomyosis  
Endometritis 
Cervicitis/Vaginitis 
 Premalignant/Malignant pelvic lesions  
Endometrial hyperplasia 
Endometrial adenocarcinoma 
B Systemic diseases 
Coagulation disorders 
Hypothyroidism 
Liver disease 
C latrogenic causes 
Hormone therapy 
Contraceptive devices/Hormones 
Anticoagulation therapy 
D Anovulation – Dysfunctional Uterine Bleeding 
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In the perimenopausal age, AUB is frequently related to DUB, 
which is either ovulatory or anovulatory. Defects in local endometrial 
hemostasis leads to ovulatory DUB,while systemic disorders that occurs 
due to the imbalance  of sex steroids in the absence of anatomic lesions 
leads to anovulatory DUB .  
Alternatively, abnormal bleeding can occur secondary to organic 
etiologies within the uterus that affect endometrial hemostasis, such as 
leiomyomas,polyps,endometrial hyperplasia and neoplasia. 
Coagulopathies though  uncommon,  should be considered in the 
differential diagnosis of AUB. Uterine leiomyomas are common, 
especially in women in the fourth and fifth decades of life28. 
ANOVULATORY DISTURBANCES:  
Endometrial atrophy (Insufficient follicular development): 
This is characterized by a complete lack of endometrial response to 
ovarian hormones. Histopathologically epithelial and stromal cells are 
small, with very sparse glands lined by low cuboidal epithelium .The  
nuclei are small, round with dense chromatin. The cytoplasm is scanty 
with no   mitoses. The stroma is made   of densely packed, spindle                      
cells 9, 27. 
Deficient proliferation: 9 
Due to central hypogonadotrophic or ovarian damage, if a growing 
follicle does not reach maturity, it remains functionally inadequate and 
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little estrogen will be produced with two consequences. 
1. In the early follicular phase , diminished concentration of  FSH causes 
insufficient feedback stimulation and the  LH levels will remain low. 
As a result,the LH peak will not develop and  ovulation does not take 
place. 
2. Due to understimulation, the endometrium will not proliferate 
adequately. The LH concentration is too low for the  induction of  
ovulation, but it  causes sporadic luteinization in the insufficient 
follicle. 
Histologically, the endometrial glands and stroma show retardation 
of growth. The glands are narrow and straight with  low columnar 
epithelium and has densely arranged chromatin rich nuclei in single row 
with scanty cytoplasm. The estrogen receptor content is low. The stromal 
cells are spindle shaped, small, poorly differentiated and are densely 
packed. The height of the endometrium is moderate, with slightly 
irregular surface. Mitoses are rare. 
Irregular proliferation: (persistent ovarian follicle): 9,10 
Although a follicle has matured normally, ovulation may not take 
place because of a central defect in LH stimulation, or of ovarian damage 
or hyperstimulation with FSH. The follicle which is unruptured and 
persistent, produce estrogen beyond the proliferation phase for a number 
of days and regress slowly, resulting in anovulatory shedding which 
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occurs at the same time as menstrual shedding, or it may be more or less 
delayed,depending upon how long the follicle persists.  
Histologically the growth of the glands and stroma exceeds that of 
the normal proliferative phase. The glands are lined by a pseudostratified 
or stratified high columnar epithelium,with varied  distribution which is 
either  closely packed or widely dispersed. On immunohistochemical 
analysis, the nuclei of the proliferating glandular epithelial cells show 
strong staining for estrogen receptors. The stroma is irregularly 
edematous  and composed of densely arranged spindle cells. The spiral 
arterioles are underdeveloped,and thin walled venules are found.  
        At times, irregular proliferation may develop into atypical 
hyperplasia, without entering  the stage of simple glandular hyperplasia. 
Perimenopausal bleeding patients with irregular proliferation should be 
carefully  followed up and their estrogen levels analyzed, to ensure that a 
long standing unopposed estrogen stimulation of the endometrium  is not 
overlooked. 
Irregular proliferation may develop focally, and these areas  show 
delayed shedding or no shedding with menstruation, because their 
reticulum fibres are not dissolved .This  can give rise to polyps which 
may grow and become pedunculated. 
  
23 
 
OVULATORY DISTURBANCES: 9,30 
The Corpus luteum insufficiency- deficient secretory phase: 
This comprises many  disturbances in corpus luteum function of 
central or ovarian origin with or without preceding abnormal 
development of follicle. When the hormonal balance shifts in favour of 
estrogen,the stimulatory effect of progesterone on the endometrium 
become  deficient.  
Irregular shedding (Persistent corpus luteum):8 
Failure of regression of  a normally  developed corpus luteum leads 
to  continuous  secretion of  progesterone and  the menstrual bleeding will 
be delayed and prolonged. Such a persistence of the corpus luteum may 
be caused  by hyperstimulation from chorionic gonadotrophin or pituitary 
as in intrauterine or extrauterine pregnancy. 
Irregular shedding is characterized by admixture of endometrial 
fragments in various stages of regression and dissociation.So the 
glandular lumen become star shaped.The cytoplasm of most of the 
glandular cells is clear and contain abundant glycogen.Nuclei are 
shrunken with dense chromatin.  
Disordered Proliferative Endometrium:9 
In  disordered proliferative endometrium there is absence of pattern 
uniformity, due to dyssynchronous growth of the functional layer of 
endometrium. In some areas,  the glands are narrow, tubular,and with 
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abundant stroma, while  in other areas the glands are cystically dilated  
with  varying degree of shallow budding. The  ratio of  gland to stroma is 
1:1. Thus, disordered proliferation,which is  commonly observed in 
perimenopausal women, differs from simple hyperplasia without 
cytological atypia(gland to stroma ratio is 3:1) by its relatively normal 
gland to stromal ratio.  
Endometrial Hyperplasia: 
Endometrial hyperplasia is a noninvasive proliferation of the 
endometrium resulting  in histomorphologic  pattern of endometrial  
glands with irregular shapes and varying size31.Endometrial exposure to 
prolonged levels of unopposed estrogen, that commonly  occurs with 
anovulation in the perimenopausal age may result in the development of 
endometrial hyperplasia32.Endometrial hyperplasia comprises  of  both  
epithelial and stromal proliferations that  has varied morphological 
patterns. 
  Endometrial hyperplasia may be  the consequence of either, 
1. A persistent follicle with high levels of estrogen for a long period. 
2. Repeated follicular atresia with hyperplasia of theca cells that secrete 
estrogen. 
3. Repeated anovulatory cycles or  polycystic ovarian disease. 
4. Recurrent severe luteal defect. 
Other causes are exogenous estrogen administration and 
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endogenous conditions that produce excessive estrogen like hilar cell 
hyperplasia, stromal hyperplasia, granulosa cell tumours and thecomas.  
Harold Fox in 198433 recognized four forms of hyperplasia, 
1. Cystic glandular hyperplasia 
2. Adenomatoid hyperplasia 
3. Glandular hyperplasia with architectural atypia 
4. Glandular hyperplasia with cytologic atypia. 
Kurman and Norris in 198634 classified hyperplasias  into  simple  and 
complex as follows: 
• Hyperplasia   :  Simple  
Complex 
• Atypical hyperplasia :  Simple 
                                                Complex 
M.C. Anderson in 199135 classified endometrial hyperplasia into, 
1. Cystic hyperplasia-graded as 
 Mild 
 Moderate  
 Severe 
2. Atypical hyperplasia 
a) Architectural atypia 
b) Cytological atypia, which is further graded into 
 Mild  
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 Moderate  
 Severe   
 Ronnett B.M and Robert J. Kurman in 200230  defined 
endometrial hyperplasia as a lesion with  increase in the gland to stroma 
ratio with  predominant  proliferation of   irregular sized and shaped 
glands. He classified hyperplasia in to  
1. Hyperplasia without cytologic atypia (non atypical hyperplasia) 
a) Simple 
b) Complex 
2. Hyperplasia with cytologic atypia (atypical hyperplasia) 
a) Simple 
b) Complex 
Simple or complex hyperplasias  were  classified  on the degree of 
glandular crowding. 
 Current classification of endometrial hyperplasia accepted by both 
the International society of Gynaecological Pathologist (ISGP) and WHO 
(2003)36 divides the hyperplasia on the basis of architectural features in to 
simple and complex, and on the basis of cytological features into typical 
or atypical.37  
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TABLE  3 :WORLD HEALTH ORGANIZATION 
CLASSIFICATION OF ENDOMETRIAL HYPERPLASIA:36,38 
 Typical Hyperplasias Atypical hyperplasias 
1. Simple hyperplasia without 
atypia  
1.Simple atypical hyperplasia 
 
2.Complex hyperplasia without 
atypia(syn.adenomatous hyperplasia 
without atypia) 
2.Complex atypical hyperplasia 
(syn.adenomatous hyperplasia with 
atypia) 
TYPICAL HYPERPLASIA: 
Typical hyperplasia comprises of : 
 Simple hyperplasia without atypia. 
 Complex hyperplasia without atypia 
SIMPLE HYPERPLASIA WITHOUT ATYPIA:39 
In simple hyperplasia without atypia, the  endometrium is 
edematous and glassy. There are marked proliferative changes and 
increased mitotic activity of  both the glands and stroma. The glands are 
cystically dilated and tortuous and have  the characteristic "Swiss 
Cheese" pattern . The cells are tall and may be high cuboidal, columnar or 
pseudostratified, depending upon the degree of  hyperplasia. The nuclei 
are elongated with dense chromatin and   large nucleoli. The activity of 
alkaline phosphatase increases, which  is directly proportional to the level 
of estrogen. Droplets of glycogen can be demonstrated. 
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The stromal cells are densely packed and plump spindle shaped 
with dense nuclei and scant cytoplasm. Granulocytes are absent. 
Cytologic atypia is rare. The reticulum fibres are irregularly distributed 
eventhough increased in number and thickness . The spiral arteries and 
arterioles are poorly developed and has  a straight course. The amount 
and duration  of hyperestrogenism determines the fate of  simple  
hyperplasia.Regressive changes may appear  if  the level of oestrogen 
falls, but if  hyperestrogenism persists simple hyperplasia progresses to 
complex hyperplasia. 
COMPLEX HYPERPLASIA WITHOUT ATYPIA 
(ADENOMATOUS HYPERPLASIA WITHOUT ATYPIA):40 
In complex hyperplasia without atypia, budding of the  glandular 
epithelium occurs , and new glands are formed. The glands are lined by 
tall columnar, stratified epithelium from which epithelial papillae develop 
and protrude into the lumen. The nuclei are elongated, large, and rich in 
chromatin but basal polarity is maintained. The cytoplasm is scant  with 
numerous mitoses. As the glands proliferate, the intervening stroma is 
compressed and gradually decreased, so that the glands are arranged in  
back to back position.  
ATYPICAL HYPERPLASIA:40 
The main feature which differentiates atypical hyperplasia from 
complex hyperplasia without atypia is the atypical cytology of the 
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glandular lining epithelium characterized by loss of axial polarity, nuclear 
pleomorphism, irregularity in the nuclear membranes, prominent nucleoli 
and dense chromatin. 
Atypical hyperplasia comprises of: 
 Simple atypical hyperplasia 
 Complex atypical hyperplasia 
SIMPLE ATYPICAL HYPERPLASIA : 
                Simple atypical hyperplasia is characterized by atypical 
glandular morphology superimposed on the architecture of simple 
hyperplasia without atypia. This pattern is extremely unusual. 
COMPLEX ATYPICAL HYPERPLASIA (ADENOMATOUS 
HYPERPLASIA WITH ATYPIA): 
Complex atypical hyperplasia  is characterized by increased 
complexity of the glandular epithelium with irregular outgrowths and 
cytological atypia. Focal areas of nonendometrioid differentiation such as 
squamous morules may be present . The interglandular stroma is present 
but diminished due to the expansion and crowding of glands. 
Characteristic features of adenocarcinoma of the endometrium  are 
absent.The assessment of cytological atypia is the key problem in 
assigning individual cases to one of the four different WHO categories of 
hyperplasia.   
  
30 
 
ENDOMETRIAL CARCINOMA:40 
Endometrial carcinoma is a primary malignant epithelial tumour,  
arising in the endometrium.This malignant tumor shows a glandular 
differentiation and can  invade into the myometrium with distant 
metastatic spread. 
Though rare in perimenopausal age, the progression rate of 
untreated endometrial hyperplasia to carcinoma is significantly higher. 
Two types of tumors are identified  
 Type I 
 Type II 
"Estrogen dependent tumours Type I" are low grade and associated 
with endometrial hyperplasia, such as atypical hyperplasia. Unopposed 
estrogen stimulation is the driving force behind type I group of tumours. 
This type is common in perimenopausal age group41,42. 
The second type (Type II) of endometrial carcinoma  is less related 
to sustained estrogen stimulation and this type commonly occurs  in 
postmenopausal  age group 41,42 . 
Endometriod adenocarcinoma is a primary endometrial 
adenocarcinoma with glands resembling the normal 
endometrium.Histopathologically,  most common type  of carcinoma of 
endometrium  is the endometrioid adenocarcinoma,which shows  
glandular or villoglandular architecture and are lined by either simple 
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columnar or  pseudostratified columnar cells . The differentiating feature 
of well differentiated endometrioid adenocarcinoma from atypical 
hyperplasia is  by stromal disappearance between adjacent glands, i.e. 
cribriform,  villoglandular patterns.  
Both typical hyperplasias and  atypical hyperplasias  may regress 
spontaneously over months or years. However, atypical hyperplasia   is a 
precancerous condition that may progress to  malignancy and  is best 
treated by  hysterectomy. Hyperplasia without atypia is known to regress 
spontaneously after D&C or progestin treatment42.Progression rate of 
untreated endometrial hyperplasia to carcinoma28,43 is shown in table 4. 
TABLE 4: PROGRESSION RATE OF UNTREATED 
ENDOMETRIAL HYPERPLASIA TO CARCINOMA 
Type of  hyperplasia Progression to carcinoma 
Simple hyperplasia without atypia  1% 
Complex hyperplasia without atypia  3% 
Simple hyperplasia with atypia 8% 
Complex atypical  hyperplasia  29% 
The most common lesion that predisposes to endometrial 
adenocarcinoma is atypical endometrial hyperplasia. If left untreated, 
approximately 8% of patients with simple atypical hyperplasia and 29% 
of patients with complex atypical hyperplasia will progress to 
carcinoma28. 
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In patients with atypia, if conserving the uterus is considered, a 
trial of hormonal treatment may be given. Steroid hormone receptor 
analysis plays an important role or may be an indication in this group of 
patients to predict their response to hormonal therapy. Steroid hormone 
receptor analysis also plays a role in predicting the prognosis of patients 
with these lesions. 
ESTROGEN AND  PROGESTERONE RECEPTORS: 44,45 
        The estrogen receptor (ER) and progesterone receptor (PR) , 
members of the steroid hormone receptor family,  act as hormone 
dependent activators of transcription. Two estrogen receptors  are 
identified, ERα and ERβ(Fig.3). ERα (60-66 kD protein) and ERβ(51-
61kDa protein) located at chromosome 6 and chromosome 14 
respectively and  are translated from two different genes. 
            Figure 3: Structure of estrogen receptor (ERα and ERβ) 
  ER alpha and beta are expressed in tissues of different types, but 
their expression pattern varies. The ERα is found in endometrium46, 
stromal cells of ovary, neoplastic cells of breast and in the hypothalamus. 
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The ERβ protein is found in kidney, lungs, intestinal mucosa, prostate, 
brain, heart, bone and endothelial cells44,47. 
The ratio of the concentration of ERα and ERβ subtype plays a 
major role in certain diseases48,49. The ability of the estrogen receptor 
modulators to promote ER interactions with various  proteins is the 
mechanism for the  concept of selective estrogen receptor 
modulators(SERM).These proteins may be  transcriptional co activator or 
co repressors50. The ratio of the  co activator to the  co repressor protein 
varies in different tissues 51 . 
The progesterone receptor (PR) NR3C3 is  a nuclear receptor 
subfamily 3, group C, member 3,and it is  an intracellular steroid receptor 
that  specifically binds progesterone. PR exists as two isotypes, A and B 
with molecular weights of approximately 95 kD protein and 120  kD 
protein(Fig.4). PRA and PRB are both  identical in  their sequence, but  
PRA lacks 164 amino acids at the N-terminus, which  makes it the shorter 
of the two proteins 52,53. 
 
Figure 4: Structure of progesterone receptor (PRA and PRB) 
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Many  functional domains can be distinguished in both ERs and 
PRs. They are the transcription regulating domain (TRD), hinge region 
(H), DNA binding domain (DBD),  ligand binding domain (LBD), 
activation function domain (AF1-3) and an inhibitory domain 
(ID).Numbers indicate the  location of  amino acid(Fig.3&Fig.4). 
Estrogen is needed for the induction of the progesterone receptors. 
Progesterone has different tissue specific effects in humans,54 and is a 
regulator of normal female reproductive function. Estrogen  amplifies  the 
action of progesterone. The action of progesterone depends on the 
presence of progesterone receptor. The expression of the progesterone 
receptors are up regulated by estrogen through the estrogen receptors 55,56.  
MODE OF ACTION OF ESTROGEN AND  PROGESTERONE 
RECEPTORS: 
The  ER ,PR receptors  are associated with heat shock proteins in 
the absence of ligand. After binding the  ligand , the conformation of the 
receptor changes and  dissociation of  heat shock proteins occur. They 
then form  receptor hormone complex dimers, homodimers for example 
ERα-ERα  and  heterodimers for example ERα-ERβ. Both ERα and ERβ 
are located in the nucleus of the cell in the absence of  ligand,and PR is 
present  either in  the cytoplasm or the nucleus, in  unliganded  state. 
After binding of  ligand,the receptor gets  activated through 
phosphorylation and both receptors ER and PR predominantly localize to 
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the nucleus. In the nucleus, these  dimers, homo or heterodimers  bind to 
specific hormone response elements (ERE or PRE) on the DNA. After the 
receptor dimer binds to the DNA, many coactivators, corepressors and 
transcription factors bind, after which the target genes are            
transcribed57.(Fig.5) 
 
Figure 5: Mode of action of estrogen and progesterone receptors.  
ER AND PR IN NORMAL ENDOMETRIUM:  
The endometrium expresses estrogen (ER) and progesterone 
receptors (PR). Throughout the menstrual cycle, the concentrations of 
both estrogen receptor (ER) and progesterone receptor (PR)  undergo 
considerable variations in the human uterus,in response to changing 
hormonal levels , and a variable  expression of  the steroid receptors in 
the  cells of epithelium and stroma of the endometrium occurs. 
36 
 
The differential expression of  steroid receptors ERα, ERβ, PRA 
and PRB in normal and atrophic endometrium were  observed by 
Mylonas I, Snijder and many authors58,59.In glandular and stromal cells of 
the endometrium, the  basalis and functionalis, significant changes were 
noted in the  receptors during the menstrual cycle. 
In the late proliferative phase of the menstrual cycle,the estrogen 
receptor expression reached a maximum, in the endometrium. The 
expression of estrogen48 receptor in the glandular epithelial cells declined  
more gradually 58  during the early secretory phase of the cycle whereas, it  
declined sharply in the stromal cells and smooth muscle cells.During mid 
secretory and late secretory phases, an increase in expression  of estrogen 
receptor was observed in the predecidualizing cells of the stroma and 
smooth muscle cells58. 
The number of  progesterone receptors in the  glandular epithelial 
cells of the endometrium  changed significantly but not in the stromal 
cells and smooth muscle cells. In the early secretory phase,the  
progesterone receptor expression in the endometrial glands reached a 
maximum and then decreased suddenly. During mid secretory phase and 
late secretory phases, PR immunostaining was moderate in the stromal 
cells in contrast to the  glandular epithelium which showed very weak 
staining or no staining 58. 
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ER AND PR IN HYPERPLASTIC AND NEOPLASTIC 
ENDOMETRIUM: 
Proliferative disorders of the endometrium are caused due to the  
autocrine and paracrine actions of estrogen and progesterone in  the 
epithelial  and stromal cells. There is a progressive loss of  PR expression  
in stromal cells of  endometrium  and this  may induce abnormal 
proliferation of endometrium due to disrupted hormonal balance60. 
Endometrial carcinoma being one of the commonest  gynecologic 
malignancies, various prognostic factors have been studied to improve the 
treatment and follow up. Prognostic significance of the steroid hormone 
receptors has been well established in breast carcinoma. Several studies 
on breast carcinoma have confirmed the validity of ER,PR 
immunohistochemistry and has shown their  prognostic and therapeutic 
usefulness.  Analogous studies in endometrial carcinoma are few and 
limited to clinocopathological correlation. 
Patients with significant numbers  of  both  estrogen and 
progesterone receptors in advanced endometrial carcinoma  tend to have 
an indolent clinical behavior than patients with absent or low level of  
these receptors.The response rate to progestins for the lesions which are 
progesterone receptor rich are better compared to progesterone receptor 
poor lesions 56. 
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Many studies have observed  the effects  of the steroid receptor 
status on survival of the patient. In a study by  Geisinger et al, on the 
survival status, he  found that quantitative levels of the progesterone 
receptor was significantly related to survival. Creasman et al. observed 
that estrogen receptor positive status, progesterone receptor positive 
status, and combined estrogen receptor and progesterone receptor positive 
status had a significantly greater disease free survival than those with 
estrogen receptor and progesterone receptor negative tumors.   Myolonas. 
I, observed  that the loss of receptor positivity for ERα in patients with 
endometrial adenocarcinoma  resulted in a poorer survival, while the loss 
of receptor positivity for ERβ did not affect the  survival61,62,63. 
IMMUNOHISTOCHEMISTRY : 
Immunohistochemistry has become necessary and an interesting 
part of diagnostic pathology due to the accuracy and ease that it imparts 
to the studies of tissues at the cellular level. Hence, it is becoming widely 
used in diagnostic research procedures. 
SCORING SYSTEM FOR ER AND PR IHC STAINING: 
Estrogen and progesterone receptors show nuclear positivity. They 
are scored by the proportion of tumor cells showing positivity and the 
intensity of the reaction. Both the scores are  summated to give a total 
score. Different scoring systems used to score estrogen and progesterone 
receptors include H scoring system,64 Quick scoring system65and Allred 
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scoring system66 .Quick scoring system that was proposed by Barnes et al  
is widely used worldwide as the score correlates well with the chance of  
patient response to hormonal  therapy 66. 
The current study has been undertaken to evaluate the 
histomorphological profile of endometrium in perimenopausal bleeding 
and to evaluate the steroid hormone receptor status in endometrial 
hyperplasias using immunohistochemical method. 
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MATERIALS AND METHODS 
This study is a prospective study of the histomorphological profile 
of endometrium in perimenopausal bleeding conducted in the Department 
of Pathology, Government Tirunelveli Medical College and Hospital 
during the period of  June  2010- October 2012. 
SOURCE OF DATA: 
The endometrial curettage specimens received in the Department 
of Pathology , Government Tirunelveli Medical College and Hospital 
during the period of  June  2010- October 2012,that are clinically 
diagnosed DUB/AUB  patients in perimenopausal age group of 40-50 
years.  
SAMPLE SIZE:  
200 cases. 
INCLUSION CRITERIA:  
All cases that are  clinically diagnosed as DUB/AUB  and are in 
the perimenopausal age group of 40-50 years.  
EXCLUSION CRITERIA: 
Endometrial curettage from patients of other age groups and 
postmenopausal  bleeding cases. 
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METHOD OF COLLECTION OF DATA: 
The endometrial curettage specimen was collected from  200 
clinically diagnosed DUB/AUB patients in perimenopausal age group of 
40-50 years.The endometrial curettage samples were fixed in 10% 
formalin, histopathological slides were prepared and stained with 
Hematoxylin and Eosin stain(Appendix 1). All cases of hyperplasia 
including  simple hyperplasia without atypia,complex hyperplasia without  
atypia,complex atypical hyperplasia and carcinoma were selected and 
their representative formalin fixed paraffin embedded tissue samples were 
subjected to immunohistochemistry for ER and PR status. The results 
were recorded with photographs. 
IMMUNOHISTOCHEMICAL EVALUATION: 
Immunohistochemical analysis of estrogen and  progesterone 
receptors were done in paraffin embedded tissue samples for all cases 
which were diagnosed as  hyperplasias, including  simple hyperplasia 
without atypia, complex hyperplasia without  atypia, complex atypical 
hyperplasia and carcinoma using  supersensitive polymer HRP system 
based on non biotin polymeric technology. 4 µ thick sections from 
formalin fixed paraffin embedded tissue samples were transferred on to 
gelatin coated slides. Heat induced antigen retrieval was done. The 
antigen is bound with mouse monoclonal antibody (Biogenex) against 
estrogen and progesterone receptors. The step by step procedure of  
immunohistochemistry is given in Appendix -2. 
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INTERPRETATION AND SCORING SYSTEM: 
 The  immunohistochemically stained slides were analysed for the 
presence of reaction, cellular localization. The percentage of cells stained  
per 1000 cells counted on 40X power field and the intensity of  reaction 
were analysed. Immunohistochemical scoring for ER and PR receptors 
were done with Quick score65.  
QUICK SCORING SYSTEM FOR  EVALUATION OF   
ESTROGEN AND PROGESTERONE RECEPTOR EXPRESSION:  
TABLE 5:   SCORE FOR PROPORTION 
Proportion of  nuclei stained Score 
No nuclear staining 0 
<1%  nuclear staining 1 
1-10%  nuclear staining 2 
11-33% nuclear staining 3 
34-66% nuclear staining 4 
67-100% nuclear staining 5 
 
The proportion of  the cells stained are observed and scored accordingly. 
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TABLE 6: SCORE FOR INTENSITY 
Intensity of  nuclear staining Score 
No staining 0 
Weak staining 1 
Moderate staining 2 
Strong staining 3 
 
The  above two scores, score for proportion and the score for 
intensity(table 5 and table 6) are summated to a total maximum  score of 
8.Score of more than 2 is considered positive. 
  
44 
 
OBSERVATION AND RESULTS 
TABLE 7: INCIDENCE OF DUB CASES COMPARED TO ALL 
GYNAECOLOGY CASES 
S.No Period 
Total no. of 
Gynaecology Cases 
No. of DUB 
Cases 
Percentage 
1 JUNE 2010-DEC 2010 1715 87 5.07% 
2 JAN 2011-DEC 2011 2704 177 6.55% 
3 JAN 2012-OCT 2012 2164 123 5.68% 
 
TOTAL 6583 387 5.88% 
In the study period from  June 2010 to October 2012, 6583 
Gynaecology biopsy specimens were received in the Department of 
Pathology,Government Tirunelveli Medical college and Hospital. Among 
them, 387 cases were DUB cases. The average incidence of  DUB cases 
were 5.88% as shown in Table 7 and Chart 1. 
TABLE 8: INCIDENCE OF PERIMENOPAUSAL  BLEEDING  
CASES COMPARED TO DUB CASES 
Total DUB Cases Perimenopausal  Bleeding cases Percentage 
387 200 51.68% 
 
Among the total number of DUB cases of  387, 200 cases were 
clinically diagnosed as DUB and are in the perimenopausal age group of 
40-50 years, which constitutes about 51.68% as shown in Table 8 and 
Chart 2. 
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TABLE 9: AGE INCIDENCE OF PERIMENOPAUSAL 
BLEEDING  CASES 
Age group No. of cases Percentage 
40-45 years 134 67% 
46-50years 66 33% 
Total 200 100% 
 
Table 9 and Chart 3 depicts the age incidence of perimenopasual 
bleeding cases. Between the age group of 40-45 years, 134 cases (67%) 
were observed and between the age group of 46-50 years 66 cases (33%) 
were observed. So the maximum incidence of perimenopasual bleeding 
were seen in the age group of 40-45years (67%). 
 
TABLE 10: DISTRIBUTION OF ENDOMETRIAL PATTERNS IN 
PERIMENOPAUSAL BLEEDING CASES 
Type of Endometrium No. of cases Percentage 
Proliferative endometrium and its variants 99 49.50% 
Secretory endometrium and its variants 12 6% 
Hyperplasias 48 24% 
Others 41 20.50% 
Total 200 100% 
 
Among the 200 perimenopausal bleeding cases, proliferative 
endometrium and its variants  constitute 99 cases (49.50%), secretory 
endometrium and its variants 12 cases (6%), hyperplasias 48 cases (24%), 
and other cases constitute 20.50%  (41cases) (Table 10& Chart 4). 
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TABLE: 11 PROLIFERATIVE ENDOMETRIUM AND ITS 
VARIANTS  
Type of Endometrium No. of cases Percentage 
Proliferative endometrium 23 23.23% 
Deficient proliferative endometrium 25 25.25% 
Disordered proliferative endometrium 26 26.26% 
Irregular proliferative endometrium 12 12.12% 
Proliferative endometrium with cystic change 3 3.03% 
Proliferative endometrium with disintegration 10 10.10% 
Total 99 100% 
 
In the total of 99 cases of proliferative endometrium and its 
variants, there were 23 cases (23.23%) of   proliferative endometrium, 25 
cases(25.25% )of deficient proliferative endometrium,26 cases(26.26% )of 
disordered proliferative endometrium, 12 cases(12.12%) of irregular 
proliferative endometrium, 3 cases (3.03%)of proliferative endometrium 
with cystic change, 10 cases(10.10% )of proliferative endometrium with 
disintegration (Table 11& Chart 5). 
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TABLE 12: AGE INCIDENCE OF PROLIFERATIVE 
ENDOMETRIUM AND ITS VARIANTS  
Type of Endometrium 
No. of cases    
40-45 years 
% 
No. of 
cases 46-50 
years 
% 
Proliferative endometrium 21 91.3 2 8.7 
Deficient Proliferative 
endometrium 
14 56.0 11 44.0 
Disordered Proliferative 
endometrium 
11 42.3 15 57.7 
Irregular Proliferative 
endometrium 
8 66.7 4 33.3 
Proliferative endometrium 
with cystic change 
1 33.3 2 66.7 
Proliferative endometrium 
with disintegration 
8 80.0 2 20.0 
Total 63  36  
Chi-square value =15.75, d.f.=5, P=0.008. 
Between the age group of 40-45 years, there were 63 cases 
(63.63%), and in the age group of 46-50 years, 36 cases (36.36 %). 
Among the 23 cases with proliferative endometrium, 91.3% were in  40-
45years age group and among the 10 cases of  proliferative endometrium 
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with disintegration, 80% of them were in 40-45 years age group. Chi-
square statistical test has been applied to find out if  there is any 
association between the type of proliferative endometrium and age of the 
person. The significant p-value infers that   disordered proliferative  
endometrium and proliferative  endometrium with cystic change  are 
more common among the women in the age group of 46-50 years 
compared to the women in the age group of 40 to 45 years. Similarly for 
the women in 40-45 years age group, proliferative endometrium and 
proliferative endometrium with disintegration is common(Table 12 & 
Chart 6). 
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TABLE13: SECRETORY ENDOMETRIUM AND ITS VARIANTS 
Type of Endometrium No. of cases Percentage 
Early secretory endometrium 3 24.99% 
Mid secretory endometrium 2 16.66% 
Late secretory endometrium 1 8.33% 
Deficient secretory endometrium 5 41.65% 
Deficient secretory with stromal haemorrhage 1 8.33% 
Total 12 100% 
 
In the total of 12 cases of secretory endometrium and its variants, 
there were 3 cases (24.99%) of early secretory endometrium,  2 cases 
(16.66%) of  mid secretory endometrium, 1 case (8.33%) of late secretory 
endometrium , 5 cases (41.65%) of deficient secretory endometrium and  1 
case (8.33%)  of  deficient secretory endometrium with stromal 
haemorrhage(Table 13& Chart 7). 
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TABLE 14: AGE INCIDENCE OF SECRETORY ENDOMETRIUM 
AND ITS VARIANTS  
Type of Endometrium 
No. of cases    
40-45 years 
% 
No. of 
cases 46-
50 years 
% 
Early secretory endometrium 3 100% 0 0% 
Mid secretory endometrium 1 50% 1 50% 
Late secretory endometrium 1 100% 0 0% 
Deficient secretory 
endometrium 
4 80% 1 20% 
Deficient secretory with 
stromal haemorrhage 
0 0% 1 100% 
Total No.of cases  9  3  
 
Between the age group of 40-45 years, there were 9 cases of 
secretory endometrium, and in the age group of 46-50 years, 3 cases were 
observed(Table 14& Chart 8). 
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TABLE 15: TYPES OF HYPERPLASIAS 
Type of Endometrium No. of cases     Percentage 
TYPICAL 
Simple Hyperplasia without atypia 42 87.50% 
Complex Hyperplasia without atypia 4 8.33% 
ATYPICAL 
 Simple Hyperplasia with atypia 0 0% 
Complex Atypical Hyperplasia  2 4.16% 
Total 48 100% 
 Chi-square with Yate’s correction value =7.45, P<0.05. 
Among the 48 cases of hyperplasia, in typical hyperplasia, simple 
hyperplasia without atypia constitute 42 cases (87.50%), complex 
hyperplasia without atypia constitute 4 cases(8.33%) , and among atypical 
hyperplasias, complex hyperplasia with atypia was 2 cases (4.16%).  Chi-
square with Yate’s correction  test has been applied to find out the 
association between the hyperplasias in total  and those without atypia   
(typical). The significant p-value indicates that  most of the endometrium 
without atypia (typical)were with simple hyperplasia                                       
(Table 15 & Chart 9). 
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TABLE16: SIMPLE HYPERPLASIA AND ITS VARIANTS 
Type of Endometrium No. of cases Percentage 
Simple Hyperplasia 29 69.05% 
Simple Hyperplasia with disintegration 2 4.76% 
Simple Hyperplasia with polyp 2 4.76% 
Simple Hyperplasia with chronic endometritis 2 4.76% 
Simple Hyperplasia with cystic change 6 14.28% 
Simple Hyperplasia with squamous 
metaplasia 
1 2.38% 
Total 42 100% 
 
Among the  total 42 cases of simple hyperplasia without atypia,the 
following patterns were observed.They were, simple hyperplasia without 
atypia 29 cases (69.05%), simple hyperplasia with disintegration 2 cases 
(4.76%) simple hyperplasia with polyp 2 cases (4.76%), simple 
hyperplasia with chronic endometritis 2 cases (4.76%), simple hyperplasia 
with cystic change 6 cases (14.28%) and simple hyperplasia with 
squamous metaplasia 1 case (2.38%)(Table 16 & Chart 10). 
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TABLE17: AGE INCIDENCE OF SIMPLE HYPERPLASIA 
Type of Endometrium 
No. of cases    
40-45 years 
% 
No. of 
cases 46-
50 years 
% 
Simple Hyperplasia 24 82.7% 5 17.3% 
Simple Hyperplasia with 
disintegration 
2 100% 0 0% 
Simple Hyperplasia with polyp 2 100% 0 0% 
Simple Hyperplasia with chronic 
endometritis 
2 100% 0 0% 
Simple Hyperplasia with cystic 
change 
5 83.33% 1 16.66% 
Simple Hyperplasia with 
squamous metaplasia 
0 0% 1 100% 
Total 35  7  
Chi-square value =1.92, P=0.75(Non-significant). 
Between the age group of 40-45 years, there were 35 cases 
(83.3%), and in the age group of 46-50 years 7 cases (16.66%). Chi-
square statistical test has been applied to find out if  there is any 
association  between the type of simple hyperplasia and age of the 
women. The non-significant p-value infers that the type of simple 
hyperplasia has no association with the age of the women(Table 17& 
Chart 11). 
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TABLE18: COMPLEX HYPERPLASIA 
Type of Endometrium No. of cases Percentage 
Complex Hyperplasia without atypia 4 66.67% 
Complex Atypical Hyperplasia 2 33.33% 
Total 6 100% 
 
Among the 6 cases of complex hyperplasia, complex hyperplasia 
without atypia were 4 cases (66.67%), complex hyperplasia with atypia 2 
cases (33.33%)(Table 18 & Chart 12). 
TABLE19: AGE INCIDENCE OF COMPLEX HYPERPLASIA 
Type of Endometrium 
No. of cases    
40-45 years 
% 
No. of 
cases 46-
50 years 
% 
Complex Hyperplasia without atypia 3 75% 1 25% 
Complex Atypical  Hyperplasia  0 0% 2 100% 
Total 3  3  
 
Between the age group of 40-45 & 46-50 years, there were 3 cases 
each of complex hyperplasia without atypia and complex hyperplasia with 
atypia( Table 19 & Chart 13). 
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TABLE 20: OTHER PATTERNS OF ENDOMETRIUM 
Type of Endometrium No. of cases 
Percentage of Total 
(200 cases) 
Disintegrating endometrium 19 9.5 % 
Irregular shedding 16 8% 
Endometrial polyp 5 2.5% 
Endometrial adeno carcinoma 1 0.5% 
  
The table 20 and Chart 14 depicts the number of cases of 
disintegrating endometrium  19 cases(9.5%), irregular shedding  16 
cases(8%), endometrial polyp 5 cases(2.5%) and endometrial 
adenocarcinoma 1 case (0.5%). 
TABLE 21: AGE INCIDENCE OF OTHER PATTERNS OF 
ENDOMETRIUM 
Type of Endometrium 
No. of cases    
40-45 years 
% 
No. of 
cases 46-
50 years 
% 
Disintegrating endometrium 12 63.16% 7 36.84% 
Irregular shedding 11 68.75% 5 31.25% 
Endometrial polyp 1 20% 4 80% 
Endometrial  adeno 
carcinoma 
0 0% 1 100% 
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The  incidence of disintegrating endometrium in the age group of 
40-45 years were  63.16%, irregular shedding 68.75%, endometrial polyp 
20% and between 46-50 years, disintegrating endometrium were 36.84%, 
irregular shedding 31.25%,endometrial polyp 80% and 100% of 
endometrial  adenocarcinoma  were observed(Table 21 & Chart 15). 
TABLE 22: INCIDENCE OF  OTHER ASSOCIATED ORGANIC 
LESIONS IN PERIMENOPAUSAL AGE 
Lesions No. of cases Percentage of Total (200 cases) 
Fibroid 37 18.5% 
Endometrial polyps 5 2.5% 
  
The  table 22 and Chart 16 depicts the other associated organic 
lesions in perimenopausal bleeding cases. There were 37 cases(18.5%) of  
fibroid uterus and  5cases(2.5%) of endometrial polyp in the current study.  
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TABLE 23: ENDOMETRIAL PATTERN IN PERIMENOPAUSAL 
WOMEN WITH FIBROID UTERUS 
Type of Endometrium No. of cases Percentage 
Proliferative endometrium 5 13.51% 
Deficient Proliferative endometrium 3 8.10% 
Disordered Proliferative endometrium 1 2.70% 
Irregular Proliferative endometrium 1 2.70% 
Irregular shedding 4 10.81% 
Disintegrating endometrium 8 21.62% 
Deficient secretory endometrium 2 5.41% 
 Simple hyperplasia 12 32.43% 
Complex hyperplasia without atypia 1 2.70% 
Total 37 100% 
 
The  predominant endometrial  pattern observed  in women 
presenting with abnormal uterine bleeding associated with fibroid uterus  
were  simple hyperplasia 12 cases, (32.43%).One case had complex 
hyperplasia without atypia 2.70% and other patterns were disintegrating 
endometrium 21.62%, proliferative endometrium 13.51%, deficient             
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proliferative endometrium 8.10%, deficient secretory endometrium  5.41%, 
and  both disordered proliferative endometrium and  irregular proliferative 
endometrium had similar percentage of  2.70%(Table 23 & Chart 17). 
TABLE 24:  AGE INCIDENCE OF OTHER ASSOCIATED 
ORGANIC LESIONS 
Lesion 
No. of cases    
40-45 years 
% 
No. of 
cases 46-
50 years 
% 
Fibroid 27 72.97% 10 27% 
Endometrial polyp 01 20% 04 80% 
  
The number of cases of perimenopausal bleeding associated with 
fibroid uterus were higher (72.97%) in 40-45 years age group compared to 
46-50 years age group  with  27%. Most  of  the cases(80% )of endometrial 
polyp were in 46-50 years age group, while in 40-45 years age group 20% 
were observed(Table 24 & Chart 18). 
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ESTROGEN AND PROGESTERONE RECEPTOR  IHC 
STAINING:        
 Positive staining of both ER and PR were seen in the nuclei of 
glands and stroma as fine granular staining. The percentage of cells 
stained and intensity of   reaction were analysed and immunohisto- 
chemical scoring for estrogen and progesterone receptors were done with 
Quick score.ER and PR showed nuclear positivity. Staining was graded in 
the epithelial as well as stromal component  in  typical  and atypical 
hyperplasias. Malignant epithelium and stroma were also graded for the 
analysis and calculation of  Quick score. Vascular smooth muscle cells 
and endothelial cells were consistently negative.  
Cases of hyperplasias and a case of malignant  endometrium  
evaluated using immunohistochemical method showed the following 
results 
Estrogen  Receptor and  Progesterone Receptor Staining in Simple 
Hyperplasia without Atypia: 
       Simple hyperplasia without atypia  showed moderate  staining 
intensity of  ER in glands and  in  the  stroma  with a mean percentage  of 
positive cells 75% in both the glands and stroma , and moderate staining 
intensity of PR in glands and  in  the  stroma  with a mean percentage  of 
positive cells 75%. 
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Estrogen  Receptor and  Progesterone Receptor Staining in Complex  
Hyperplasia without Atypia: 
Complex hyperplasia without atypia  showed moderate staining 
intensity of  ER(mean % of positive cells 75%) and PR (mean % of 
positive cells 85%) in  both glands and stroma. 
Estrogen  Receptor and  Progesterone Receptor Staining in Complex 
Atypical Hyperplasia  : 
Complex atypical hyperplasia showed moderate staining intensity 
of  ER in glands , weak staining in stromal cells(mean% of positive cells 
60%) and  moderate intensity levels of  PR in both glands and stroma 
(mean % of positive cells 70%).    
Estrogen  Receptor and  Progesterone Receptor Staining in 
Neoplastic case: 
One case of endometrial adenocarcinoma reported in the current 
study showed moderate staining intensity of  ER in the  glands and 
stroma (mean % of positive cells 45%) and moderate staining intensity of  
PR  in the glands and weak staining in stromal cells (mean % of positive 
cells 45%). 
The percentage of cells stained  per 1000 cells counted on 40X 
power field and the intensity of   reaction were analysed and immunohisto 
-chemical scoring for estrogen and progesterone receptors were done with 
Quick score which showed the following observations. 
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TABLE 25: ESTROGEN  RECEPTOR  EXPRESSION 
Type of Endometrium Glandular cells Stromal cells 
Simple hyperplasia without atypia Positive Positive 
Complex Hyperplasia without atypia Positive Positive 
Complex Atypical  Hyperplasia  Positive Positive 
Endometrial adenocarcinoma Positive Positive 
 
Estrogen  receptor  expression of all cases were positive in glandular 
and stromal  cells . 
TABLE 26: PROGESTERONE  RECEPTOR  EXPRESSION 
Type of Endometrium Glandular cells  Stromal cells 
Simple hyperplasia without atypia Positive Positive 
Complex Hyperplasia without atypia Positive Positive 
Complex Atypical Hyperplasia  Positive Positive 
Endometrial  adenocarcinoma Positive Negative 
      
Progesterone  receptor  expression  in simple hyperplasia without 
atypia, complex hyperplasias were positive  in glandular cells and stromal 
cells according to Quick score. In endometrial  adenocarcinoma, 
progesterone  receptor  expression were positive in glandular cells and 
negative in the stromal cells. 
            The micro-photographs of some of the slides have been presented 
in Figures 6-21.  
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DISCUSSION 
 Dysfunctional uterine beeding continues to be one of the most 
frequently encountered  problems in Gynaecological practice. In the 
study period from  June 2010 to October 2012, 6583 Gynaecology biopsy 
specimens were received in Government Medical College, Tirunelveli. 
Among them, 387 were DUB cases.  
TABLE 27: INCIDENCE OF DUB IN VARIOUS STUDY CENTRES 
Study Centres Incidence of DUB (%) 
Kamla Nehru Memorial Hospital, 
Allahabad.67 
8.32% 
AIIMS, New Delhi.68 5.3% 
Tirunelveli medical college, Tirunelveli 5.88% 
 
The average incidence of  DUB cases in our institution was 5.88% 
as evident from table 27. Similar studies done in other study centres such 
as Kamla Nehru Memorial Hospital Allahabad, and  AIIMS New Delhi 
showed an incidence of 8.32% and 5.3%  respectively. 
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TABLE 28:  INCIDENCE OF  PERIMENOPAUSAL BLEEDING 
CASES 
Authors 
Total No. of 
Cases studied 
40-50  years 
No.of cases Percentage 
Sutherland 13 (1950) 1000 362 36.2% 
Anusuya Das69 (1964) 117 38 32.5% 
Bhattach arji 70   (1964) 164 44 26.8% 
Muzaffar et al71 (2005) 260 124 48% 
Baral R et al 72 (2011) 300 140 46.66% 
Current Study 387 200 51.68% 
 
 Authors like Sutherland13 have reported highest incidence of 
abnormal uterine bleeding  in  40-50 years age group, compared to other 
age groups. Similarly Anusuya Das69  reported the incidence of abnormal 
uterine bleeding of 32.5% in the age group of 40-50 years. Bhattacharji 
(1964)70 reported highest incidence(46.66) in the  age group 40-50 
years,while in his study the incidence in other age groups were  
lower. Muzaffar et al71 and Baral R et al 72, reported an incidence of 48% 
and 46.66% respectively. In the current study, the incidence of 
perimenopausal bleeding was 51.68%. 
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TABLE 29: DISTRIBUTION OF AGE 
Authors Total No. of cases 40-45 years 
Archana Bhosle et al73 112 76.1% 
Current study 200 67% 
 
 Archana Bhosle et al73conducted a study for a duration  of 6 
months on 112 perimenopausal women who presented with abnormal 
uterine bleeding, of which 76.1% (85 cases) were in 40-45 years age 
group.In comparision with the above mentioned study, current  study also 
showed higher percentage , 67%(134 cases) in the age group of 40-45 
years. 
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TABLE 30: PATTERNS OF  ENDOMETRIUM 
Histopathological 
Diagnosis 
Shazia et 
al(2010)74 
Layla et 
al(2011)75 
Current 
Study(2013) 
Proliferative endometrium and its variants 24% 15.4% 49.5% 
Secretory endometrium and its variants 26% 16.6% 6% 
Simple(cystic) hyperplasia  25% 10.5% 21% 
Complex hyperplasia 
without atypia 
1% 1.8% 2% 
Complex atypical hyperplasia  1% 0.54% 1% 
Malignancy 0% 1.5% 0.5% 
  
Among the various patterns of endometrium observed,the  number 
of cases of proliferative endometrium and its variants  were higher 
(49.50%) in the present  study  in comparision to other studies of  Layla 
et al 75and Shazia et al74. 
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TABLE 31: COMPARATIVE ANALYSIS OF HPE OF 
PROLIFERATIVE ENDOMETRIUM IN PERIMENOPAUSAL 
BLEEDING CASES73 
Place Period 
No. of  
cases 
Proliferative 
Endometrium 
Jordan university Oct-1998-2000 116 53% 
LTMMC and Sion hospital 1/5/2007-30/10/2007 112 66.1% 
Current study June 2010-October 
2013 
200 49.50% 
 
In the present  study proliferative endometrium and its variants  
were higher, (49.50%) similar to the studies conducted in other hospitals 
as  shown in table 31. 
Among the cases of  proliferative endometrium and its variants in 
the present study,the  disordered proliferative endometrium were 
higher(26.26%)and  the incidence increased with increasing  age( 46-50 
years- 57.7%).This result correlates with the study done by                           
Baral R et al72. 
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SECRETORY ENDOMETRIUM: 
TABLE 32: INCIDENCE OF SECRETORY ENDOMETRIUM 
Authors 
Secretory  
Endometrium (%) 
Shazia et al74 26% 
Archana Bhosle  et al 73 16.1% 
Layla et al75 16.6% 
Current study 6% 
  
 In the study of Archana  Bhosle et al73 and Layla et al75 secretory 
endometrium and its variants were 16%, and the  study of  Shazia et al 74 
had an incidence of 26%. In the present study secretory endometrium and 
its variants constituted 6%.      
Among the cases of  secretory endometrium and its variants in the 
present study,the incidence of  early secretory endometrium were 24.99% 
and  the age incidence of secretory endometrium were higher (74.99%)in 
40-45 years age group. 
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ENDOMETRIAL HYPERLASIAS:  
TABLE 33: INCIDENCE OF ENDOMETRIAL HYPERPLASIA IN 
PERIMENOPAUSAL BLEEDING  
Authors 
Precentage of Cases  With  
Endometrial Hyperlasias 
 Naheed Moghal76 36.84% 
Fouzia Adil77 41.6% 
Present Study 24% 
 
 Naheed Moghal76 studied 114 patients with abnormal uterine 
bleeding in perimenopausal age group, of which  42 patients had 
endometrial hyperplasia (36.84%) . In the study of Fouzia Adil77 he 
observed that the incidence of cystic hyperplasia and adenomatous 
hyperplasia  were 32.8% was 8.8% respectively.Another study done by  
Jalil R78 showed and incidence of 14.42% of endometrial hyperplasia.The 
incidence of endometrial hyperplasia in the present study was 24% . 
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 SIMPLE HYPERPLASIAS 
TABLE 34: COMPARATIVE STUDY OF SIMPLE                
HYPERPLASIAS  OF THE ENDOMETRIUM 
Place of study Period 
No. of cases 
studied 
Simple hyperplasia 
without  atypia 
LTMMC and Sion 
hospital73 
1/5/2007-
30/10/2007 
112 17.8% 
Shazia et al74 
January to 
December 2007. 
100 25% 
Current study 
June 2010 to 
October 2012 
200 21% 
 
Of the total 200 cases of perimenoupausal bleeding, the incidence 
of simple hyperplasia  without  atypia in the present study were 21% 
which is in concurrence with the study of  Shazia et al74(25%) and  in the 
study  of Archana Bhosle et al 73 17.8% were observed,as shown in                      
table 34. 
In the present study among the 48 cases of endometrial 
hyperplasias,simple hyperplasia without  atypia was most common,with a 
total of  42 cases (87.50%) similar to the study of Amera Takreem et al79, 
who observed 66.6% of simple hyperplasia without atypia in 100 
perimenopausal bleeding patients.  In our study, 4 cases were  complex 
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hyperplasia without atypia (8.33%) and 2 cases were complex atypical 
hyperplasia (4.16%). The present study also revealed maximum number 
of cases of endometrial hyperplasia in the age group of 40-45 years. 
Simple hyperplasia with  atypia  which is  extremely unusual40 were  not 
observed in our study. 
Complex hyperplasia without atypia were 2% in the present study 
similar to the study of  Layla et al75.Complex atypical  hyperplasia were 
1%,similar to the study of Shazia et al 74(1%),and the incidence were 
observed to be increasing with increasing age(2 cases,46-50 years). 
ENDOMETRIAL  ADENOCARCINOMA 
Lyla et al75 observed that  the incidence of endometrial carcinoma 
in perimenopausal age group was 1.5%. 1 case (0.5%) of endometrial 
adenocarcinoma were observed in the present study.  
OTHER  ASSOCIATED ORGANIC LESIONS: 
Fibroid uterus: 
In the current study, most of the cases of  perimenopausal bleeding 
with  fibroid uterus fall in the age group of 40-45 years(72.97%). The 
number of perimenopausal bleeding cases associated with fibroid uterus 
were 37 cases(18.5%) and in  the study of Archana Bhosle et al73 ,it was 
49.1%. According to Teleman S et al, 2003,the most frequent  pattern of 
endometrium,in abnormal uterine bleeding was simple hyperplasia.          
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In the present study, the  predominant pattern observed in 
perimenopausal bleeding cases associated with fibroid uterus is  simple 
hyperplasia 12 cases,( 32.43%).One case showed complex hyperplasia 
without atypia(2.70%),and the other patterns were disintegrating 
endometrium 21.62%, proliferative endometrium 13.51%, deficient 
proliferative endometrium  8.10%, deficient secretory endometrium 5.41% 
and  both disordered proliferative and  irregular proliferative endometrium                       
were  2.70% . 
Endometritis  
In the study of  Baral R et al72 the incidence of chronic 
endometritis was  (2.7%) which was  equally distributed in reproductive 
age group and in perimenopausal age.In our study, 2 cases of chronic 
endometritis were observed. 
Endometrial polyps  
The prevalence of endometrial polyps in the general population is 
about  24%.  In the  study  of  Baral R et al72 he observed 4 (1.3%) of the 
cases having polyp in the perimenopausal age group. In the present  study 
we observed 5(2.5 %)  cases of endometrial  polyp in which  80% of the 
cases were  in the age group of 46-50 years. 
Lyla et al75 observed that  the incidence of endometrial polyp rises 
as age increases, has a maximum incidence in fifth decade of life and  
declines gradually after menopause80.The present study showed an 
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increasing incidence of endometrial polyps in older age group 46-50 
years(80%).Our result is comparable to other studies81. 
ESTROGEN AND PROGESTERONE RECEPTORS: 
Hyperplasia  in perimenopausal women is  a major cause of  
abnormal uterine bleeding. The transition from complex hyperplasia to  
carcinoma of endometrium was reported to occur at rates of 26.7% and  
29% by Wentz et al and Allahbadia G. et al respectively.This  shows  the 
importance of detection of  hyperplasias  in preventing the disease 
progression to more advanced stages82. 
Samhita Chakraborty et al  (2005) 83suggested  that  increased ER 
and PR lead to a local unopposed estrogen effect. This up regulates 
estrogen and progesterone receptor protein and  this cycle leads to 
hyperplasia of  the endometrium , if  the stimulus  persists. Endometrial 
hyperplasia which  is a potential precancerous lesion of the 
endometrium,84 may show altered expression of sex hormone receptors. 
Hormonal therapy is an effective treatment strategy in the management of 
patients with perimenopausal bleeding  and it supports the role of these 
receptors in the etiopathogenesis of hyperplasias83. 
Nyholm et al84   reported that  ER and PR levels were high in 
simple and complex hyperplasia without atypia, and low in simple 
hyperplasia with atypia and complex atypical hyperplasia and much 
lower in adenocarcinoma.  
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In the study by Daniela et al,85 of endometrial hyperplasias , 100% 
of endometrial hyperplasias were positive for stromal and epithelial PR . 
Daniela et al85, Samhita Chakraborty et al 83 and Nyholm et al. 84  
observed that the mean score of  ER and PR decreased in  cases of 
hyperplasias with atypia  as compared to hyperplasias without atypia. 
Samhita Chakraborty et al 83 suggested  that the sex steroid receptors may 
not be the only factor responsible for hyperplasias. There may be other 
factors responsible for  changes leading to atypia and carcinoma, that may 
down regulate the receptors in atypical hyperplasias. 
In the study  of  Daniela et al(2012)85,  it  was observed that the  
percentage of positive cells for estrogen receptors were 41.50% for 
simple hyperplasia,72.3% for complex hyperplasia,57% for complex 
atypical hyperplasia,28.5% for endometrial adenocarcinoma and the  
percentage of positive cells for progesterone  receptors were 43.8% for 
simple hyperplasia,78.5% for complex hyperplasia,75.4% for complex 
atypical hyperplasia,29.5% for endometrial adenocarcinoma. 
In the current study,  the highest values of  percentage of positive 
cells for estrogen receptors (ER)were observed in case of simple  
hyperplasia without atypia 75% and complex hyperplasia without atypia 
75%, followed by complex atypical hyperplasia with 60%. The 
percentage of positive cells for estrogen receptors in endometrial 
adenocarcinoma  was 45% . 
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Analyzing the PR expression of various types of endometrial 
hyperplasia, we observed that complex hyperplasia without atypia  has 
the  highest mean values of  percentage of positive cells for progestrone 
receptors  (85%), followed by simple hyperplasia without atypia  (75%) 
and complex atypical hyperplasia (70%). The endometrial 
adenocarcinoma, had a  percentage of 45% . 
In the present study,we  observed that the mean score of  ER and 
PR decreased in  cases of hyperplasias with atypia and endometrial 
adenocarcinoma as compared to hyperplasias without atypia, which is in 
concurrence with the above mentioned studies of  Daniela et al85, Samhita 
Chakraborty et al 83 and Nyholm et al 84.After a comparative analysis85 it 
was noted that, of  ER and PR expression, progesterone receptors are 
better expressed than estrogen receptors. Thus, for every morphological 
pattern  of  the endometrium analyzed  in this study, the average values 
for PR were higher compared with average values of  ER for similar 
lesions. 
One case of endometrial adenocarcinoma reported in the current 
study showed moderate staining of  ER and   PR  in the glands and weak 
staining in stromal cells. A large array of clinical and pathologic factors 
have been shown to play significant roles in determining the patient's 
prognosis in  carcinoma of the endometrium4. Currently, the steroid 
hormone receptor status of carcinoma of the endometrium has been 
demonstrated to be prognostically important.  
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Both  typical hyperplasias and atypical hyperplasias may regress 
spontaneously over months or  few years. However, atypical  hyperplasia  
is a precancerous condition that may progress to  malignancy and  best 
treated by surgery with hysterectomy. Hyperplasia without atypia   
regresses  spontaneously after D&C or progestin treatment42,83. In patients 
with atypical  hyperplasia, if conserving the uterus is considered, a trial of 
hormonal treatment may be given4,86. Progesterone receptor rich lesions 
have a better  response rate to progestins than lesions which are 
progesterone receptor poor 56. 
Analysis  of the steroid hormone receptors play   an important role 
or may be an indication in perimenopausal bleeding  patients to predict 
the response   to hormonal therapy4,83. Immunohistochemistry explains 
the  response of the patient to hormonal therapy in cases of  hyperplasia 
of endometrium,  and suggest that, in these cases, there are many  
alterations of  the cellular DNA, but does not allow the prediction of  the 
cases of  atypical hyperplasia which will  progress  into endometrial 
carcinoma85. In our study, the cases of  atypical  hyperplasia  which are 
steroid receptor positive,might   have responded well if these patients 
were given hormonal therapy4. 
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Immunohistochemical analysis of  the  Estrogen and  Progesterone 
receptors  in hyperplasia of endometrium, and carcinoma of 
endometrium, allows a more specific determination of  the cell  ER,PR 
receptor content and hence yields a more accurate prediction of  the 
response of the patient  to endocrine therapy. These studies should 
facilitate the development of rational strategies for the prevention and 
treatment of grave and lethal endometrial disorders. 
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SUMMARY &  CONCLUSION 
Our study throws a light on many important facts about 
perimenopausal bleeding  
The  present study revealed that the incidence of DUB in our 
institution during the study period  is  5.88%, among which,  
perimenopausal bleeding cases(40-50 years) constituted   51.68%. 
The distribution of cases of  perimenopausal bleeding  was  
maximum in the age group of 40-45 years(67%) compared to 46-50 
years. 
The most common histological pattern of endometrium  observed  
was proliferative endometrium and its variants (49.50%).Among  
hyperplasias, which constituted 24% of the total cases, simple hyperplasia 
without atypia was higher  ( 87.50%). In the total of  6 cases of complex 
hyperplasia, 66.67% was  complex hyperplasia without atypia and  
33.33%  complex atypical hyperplasia,  and they were equally distributed 
between the age group of 40-45 & 46-50 years. The  other associated 
organic lesions in perimenopausal age was  fibroid uterus 18.5% and 
endometrial polyps 2.5% and the  predominant pattern of endometrium  in 
perimenopausal women with fibroid  uterus was  simple hyperplasia 
32.43%. 
Analysing the ER, PR expression by immunohistochemical method 
revealed that there is significant difference in the epithelial and stromal 
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expression of PR between simple hyperplasia and complex   
hyperplasia.Among ER and PR expression, progesterone receptors were 
better expressed than estrogen receptors. Thus, for every morphological 
aspect of the endometrium analyzed  in this study, the mean values for PR 
were higher compared with mean values of  ER for similar lesions.The 
cases of  atypical  hyperplasia  which were  steroid receptor 
positive,might   have responded well if these patients were subjected to  
hormonal therapy4,86. The response rate to progestins for the lesions 
which are progesterone receptor rich are better compared to progesterone 
receptor poor lesions 56.Analysis  of the steroid hormone receptors play   
an important role or may be an indication in perimenopausal bleeding  
patients to predict the response   to hormonal therapy. 
The immunohistochemical studies of ER and PR in endometrial 
hyperplasia and its significance on  the prognosis  of  the disease  and 
hormonal therapy are few in the medical  literature compared to receptor  
studies on breast cancer. Our data will  definitely be  an important 
addition to the existing literature.However,further studies have to be 
conducted  in future on a large number of cases for a period of 5-10 years 
to assess the actual role of estrogen and progesterone receptor expression 
in Indian population and to explore the possibility of using these 
receptors as a novel prognostic marker and to predict the response to 
hormonal therapy.   
 Figure 6:Simple Hyperplasia without 
atypia(H&E,100X) 
 
 
 
 
Figure 8: Simple Hyperplasia without 
atypia(ER,400X) 
 
Figure 7:Simple Hyperplasia without 
atypia(H&E,400X) 
 
 
 
 
Figure 9: Simple Hyperplasia without 
atypia(PR,400X) 
 Figure 10:Complex Hyperplasia without 
atypia(H&E,100X) 
 
 
Figure 12: Complex Hyperplasia without 
atypia(ER,400X) 
 
 
Figure 11: Complex Hyperplasia without 
atypia(H&E,400X) 
 
 
Figure 13: Complex Hyperplasia without 
atypia(PR,400X) 
 
 Figure 14:Complex Atypical Hyperplasia 
(H&E,100X) 
 
 
 
Figure 16:Complex Atypical 
Hyperplasia(ER,400X) 
 
 
Figure 15:Complex Atypical Hyperplasia 
(H&E,400X) 
 
 
Figure 17:Complex Atypical 
Hyperplasia(PR,400X) 
 Figure 18: Endometrial 
adenocarcinoma(H&E,100X) 
 
 
 
Figure 20: Endometrial 
adenocarcinoma(ER,400X) 
 
 
Figure 19: Endometrial 
adenocarcinoma(H&E,400X) 
 
 
 
Figure 21: Endometrial 
adenocarcinoma(PR,400X) 
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APPENDIX -1 
HAEMATOXYLIN AND EOSIN STAINING PROCEDURE: 
1. Dewaxed sections were hydrated through graded alcohols to water. 
2. Stained in alum haematoxylin   for 7 min. 
3. Washed well in running tap water for 5 minutes. 
4. Differentiated in acid alcohol for 5 seconds. 
5. Washed well in running tap water till the sections are blue for 
5minutes. 
6. Stained with 1% Eosin Yellow for 3minutes. 
7. Washed in running tap water for 5minutes. 
8. Dehydrated through alcohols, cleared with xylene and mounted 
with DPX. 
John D.Bancroft, Alan Stevens; “Theory and Practice of 
Histological Techniques”, 4th Ed; Churchill Livingstone; 1996 ;104. 
 
 
 
 
 
 
 
    
APPENDIX- 2 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4µ thick sections are cut from formalin fixed paraffin embedded 
tissue samples and are transferred to gelatin-chrome alum coated 
slides. 
2. The slides are incubated overnight at 58ºC . 
3. The sections are deparaffinized for 15 minutes x 2 changes, in 
xylene. 
4. The sections are dehydrated for 5 minutes x 2 changes, with 
absolute alcohol . 
5. The sections are washed for 10 minutes in tap water. 
6. The slides are then immersed for 5 minutes in distilled water. 
7. Using microwave oven, heat induced antigen retrieval was done 
with appropriate buffer for 20 to 25 minutes, in appropriate 
temperature . 
8. The slides are cooled to room temperature and washed for 5 
minutes in running tap water. 
9. The slides are then rinsed for 5 minutes in distilled water. 
10. Wash the slides for 5 minutes x 2 changes with appropriate wash 
buffer (phosphate buffer). 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides for 5 minutes x2 changes, in phosphate buffer. 
13. The sections are covered with power block for 15 minutes. 
14. Appropriate primary antibody is applied over the sections and 
incubated for 45 minutes, after draining the sections. 
15. The slides are covered for 30 minutes with SuperEnhanser. 
16. The slides are washed for 5 minutes x2 changes, in phosphate 
buffer. 
17. The slides are covered for 30 minutes with SS Label. 
18. Wash the slides for 5 minutes x2 changes, in phosphate buffer. 
19. Prepare DAB substrate by diluting 1 drop of  DAB chromogen to 
1ml of DAB buffer. 
20. DAB substrate solution is applied for 8 minutes on the section. 
21. Wash the slides for 5 minutes x2 changes, in phosphate buffer. 
22. Wash the slides for 5 minutes, in running  tap water. 
23. Counterstain the sections with Hematoxylin stain for 2 seconds   
(1 dip). 
24. The slides are washed for 3 minutes in running  tap water. 
25. The slides are air dried,cleared with xylene and mounted using 
DPX. 
 
                                                    
 
 
APPENDIX- 3 
HISTOMORPHOLOGICAL PROFILE  OF ENDOMETRIUM  
IN PERIMENOPAUSAL  BLEEDING  
PROFORMA  
 
CASE NO:      PATH.BIOPSY NO:  
PATIENT NAME:  
AGE:  
IP/ OP. NO. : 
UNIT/ WARD :  
CLINICAL DIAGNOSIS:   
ASSOCIATED ORGANIC LESIONS: 
             FIBROID /  ENDOMETRIAL POLYP.  
HPE DIAGNOSIS:  
IMMUNOHISTOCHEMICAL STAINING: YES / NO 
IHC STAINING DONE :  ER / PR / BOTH ER&PR. 
INTENSITY OF STAINING: 
     GLANDS:   STROMA:   MEAN: 
QUICK SCORE FOR INTENSITY:  
PROPORTION OF CELLS STAINED: 
     GLANDS:   STROMA:   MEAN:                         
 QUICK SCORE FOR PROPORTION : 
 TOTAL SCORE  (INTENSITY+PROPORTION) : 
 QUICK SCORE RESULT :  POSITIVE / NEGATIVE 
1 975/10 40 23739 DUB SHWA
2 990/10 40 23214 DUB SHWA
3 991/10 41 23409 DUB  DPE
4 1030/10 43 23404 DUB SHWA
5 1031/10 45 25108 DUB SHWC
6 1040/10 40 24343 DUB SHWP
7 1042/10 43 25629 DUB SHWA
8 1086/10 48 26510 DUB DPE
9 1087/10 45 26227 DUB IS
10 1088/10 45 26514 DUB PE
11 1089/10 50 23905 DUB SHWS
12 1128/10 45 26049 DUB DPE
13 1129/10 50 25996 DUB PEWC
14 1184/10 50 27969 DUB DE
15 1287/10 43 31750 DUB SHWA
16 1355/10 40 31523 DUB SHWA
17 1452/10 42 33880 DUB DS
18 1453/10 45 32695 DUB IPE
19 1482/10 43 33242 DUB DE
20 1499/10 50 34030 DUB DPE
21 1504/10 47 32583 DUB MS
22 1536/10 40 36819 DUB PEWD
23 1538/10 45 34888 DUB IPE
24 1831/10 48 34939 DUB DE
25 1877/10 46 37168 DUB DE
26 1963/10 47 37312 DUB DPE
27 2088/10 40 42896 DUB SHWA
28 2156/10 45 44948 AUB(P) EP
29 2202/10 45 45825 AUB(F) SHWA
30 2232/10 46 40717 DUB DPE
31 2240/10 47 46882 AUB(F) DPE
32 2242/10 47 46894 AUB(F) DEF.PE
33 2270/10 48 45876 DUB PEWC
34 2275/10 48 46224 DUB SHWA
35 2288/10 41 48083 AUB(F) SHWA
36 2324/10 45 48818 DUB SHWA
37 2416/10 48 49555 DUB DPE
38 2417/10 49 50733 AUB(F) SHWC
39 2418/10 45 51075 DUB IS
40 2453/10 44 53056 DUB IS
41 2484/10 44 52739 DUB DPE
42 2486/10 44 52696 DUB DPE
43 2488/10 40 52684 DUB SHWE
44 2502/10 45 533355 DUB SHWD
45 2505/10 45 51951 DUB IS
46 2530/10 44 52405 DUB DPE
47 2633/10 45 56219 DUB DEF.PE
48 2635/10 48 57590 DUB DEF.PE
49 2639/10 48 56986 DUB DEF.PE
MASTER CHART
Sl. No. Age (Years) I.P No. Clinical Diagnosis DiagnosisBiopsy Number
50 2640/10 45 57097 DUB DEF.PE
51 20/11 43 56261 DUB PEWD
52 26/11 44 54972 DUB CHWA
53 28/11 40 58315 DUB DEF.PE
54 29/11 42 58304 DUB IPE
55 33/11 46 645 DUB IS
56 62/11 42 58182 DUB DS
57 71/11 40 1725 DUB IPE
58 72/11 48 974 DUB IS
59 102/11 45 968 DUB DEF.PE
60 103/11 41 2744 DUB DEF.PE
61 113/11 48 3936 DUB  DEF.PE 
62 115/11 44 3096 DUB DEF.PE
63 168/11 46 2560 DUB IPE
64 173/11 47 3964 DUB DEF.PE
65 187/11 42 4529 DUB DEF.PE
66 189/11 40 4829 DUB IS
67 195/11 44 5034 DUB CHWA
68 226/11 40 1795 AUB(F) DS
69 228/11 41 5610 DUB PEWD
70 229/11 50 5220 DUB DPE
71 267/11 46 7697 DUB IS
72 268/11 45 3284 DUB ES
73 283/11 45 7297 AUB(F) DEF.PE
74 311/11 44 7656 AUB(F) SHWC
75 325/11 43 8566 AUB(F) DS
76 365/11 45 9479 DUB IS
77 374/11 48 9631 DUB DPE
78 377/11 50 9449 DUB DE
79 432/11 44 12506 DUB PEWD
80 437/11 50 11148 DUB DEF.PE
81 455/11 45 11870 DUB IPE
82 461/11 40 12111 DUB SHWE
83 662/11 40 1204 AUB(F) SHWA
84 680/11 40 11810 DUB DEF.PE
85 687/11 43 12827 DUB PE
86 716/11 49 12593 AUB(F) DE
87 730/11 49 14281 DUB DEF.PE
88 768/11 45 14636 DUB DEF.PE
89 824/11 42 16905 DUB PE
90 859/11 45 14159 DUB SHWC
91 888/11 45 17465 DUB PEWC
92 945/11 47 19640 DUB SHWA
93 998/11 43 21059 DUB DPE
94 1034/11 44 21678 AUB(F) SHWA
95 1036/11 40 22089 AUB(F) PE
96 1039/11 50 21150 AUB(P) EP
97 1043/11 43 23251 DUB CHWA
98 1102/11 49 22305 AUB(P) EP
99 1105/11 40 23087 DUB SHWP
100 1143/11 49 24203 AUB(P) EP
101 1144/11 45 25056 AUB(F) SHWA
102 1337/11 45 26575 AUB(F) DEF.PE
103 1361/11 40 27161 DUB SHWA
104 1362/11 48 28433 DUB DS
105 1363/11 42 27975 DUB PEWD
106 1393/11 47 27539 DUB DPE
107 1431/11 42 28136 DUB DPE
108 1433/11 41 28927 DUB PEWD
109 1462/11 45 29255 DUB DPE
110 1482/11 47 30509 DUB DPE
111 1511/11 43 30501 AUB(F) DE
112 1542/11 40 31702 AUB(F) DE
113 1551/11 45 33311 DUB DPE
114 1553/11 42 32727 AUB(F) DE
115 1643/11 48 34517 DUB DPE
116 1647/11 40 34512 DUB MS
117 1756/11 45 36021 AUB(F) PE
118 1757/11 44 38223 DUB DPE
119 1779/11 45 34722 DUB DE
120 1801/11 42 38261 DUB DE
121 1802/11 46 38397 DUB DPE
122 1842/11 50 40988 DUB CAH
123 1861/11 42 39223 DUB DE
124 1888/11 50 40511 DUB PE
125 1889/11 50 39392 DUB DE
126 1894/11 40 41633 DUB LS
127 1898/11 45 41006 AUB(F) DE
128 1899/11 45 40139 DUB DPE
129 1908/11 45 41182 DUB PE
130 1957/11 46 41821 DUB DPE
131 2095/11 40 45281 AUB(F) SHWA
132 2139/11 44 45084 DUB ES
133 2166/11 48 46026 DUB PEWD
134 2231/11 45 47071 DUB SHWC
135 2260/11 50 47303 DUB DEF.PE
136 2316/11 40 50052 AUB(F) SHWC
137 2379/11 50 50631 DUB SHWA
138 2382/11 43 51402 DUB SHWA
139 2403/11 40 53434 AUB(F) IS
140 2404/11 40 51987 AUB(F) SHWA
141 2410/11 49 50908 DUB SHWA
142 2411/11 46 53596 DUB DEF.PE
143 2432/11 45 53229 DUB DEF.PE
144 2447/11 43 53040 DUB PEWD
145 2450/11 41 54742 DUB SHWA
146 2460/11 46 52624 DUB DSSH
147 2486/11 40 54446 DUB PE
148 2548/11 45 55559 DUB SHWD
149 2551/11 40 55908 AUB(F) PE
150 2572/11 50 54883 DUB DPE
151 004/12 49 60926 AUB(P) EP
152 100/12 47 50989 AUB(F) IS
153 130/12 42 2187 AUB(F) IPE
154 176/12 50 1721 DUB IPE
155 182/12 45 2820 DUB PE
156 185/12 40 3265 AUB(F) IS
157 226/12 43 2931 DUB DEF.PE
158 309/12 47 5833 DUB PEWD
159 373/12 40 6694 DUB PE
160 375/12 45 6733 AUB(F) PEWD
161 535/12 45 9989 AUB(F) IS
162 676/12 41 10416 DUB IPE
163 723/12 44 13835 DUB ES
164 727/12 42 16283 DUB PE
165 730/12 42 15228 DUB SHWA
166 746/12 44 13889 DUB PE
167 748/12 44 16680 DUB PE
168 749/12 43 16743 DUB PE
169 834/12 43 19269 DUB PE
170 866/12 46 17401 DUB CAH
171 870/12 45 16288 DUB PE
172 920/12 40 22337 DUB IS
173 981/12 48 21442 AUB(F) SHWA
174 1009/12 42 23585 DUB SHWA
175 1139/12 50 27157 DUB DEF.PE
176 1150/12 48 28390 DUB DPE
177 1215/12 40 31888 AUB(F) SHWA
178 1216/12 43 30128 DUB SHWA
179 1222/12 41 30411 DUB PE
180 1254/12 50 25915 DUB EACA
181 1255/12 40 23860 DUB SHWA
182 1391/12 45 35319 DUB PE
183 1404/12 45 36605 DUB IS
184 1409/12 47 36537 DUB IS
185 1424/12 43 37020 DUB PE
186 1444/12 45 36608 DUB DE
187 1478/12 45 38429 DUB PE
188 1507/12 50 39516 AUB(F) CHWA
189 1585/12 48 40907 AUB(F) PE
190 1586/12 49 40294 AUB(F) DE
191 1635/12 48 43161 DUB IPE
192 1652/12 42 44605 DUB IPE
193 1659/12 41 44756 DUB SHWA
194 1696/12 45 44201 DUB DE
195 1728/12 48 44719 DUB IPE
196 1729/12 49 46060 AUB(F) DE
197 1730/12 41 44756 DUB PE
198 1732/12 45 47215 AUB(F) DE
199 1862/12 49 49904 DUB DEF.PE
200 1957/12 40 51819 DUB DEF.PE
KEY TO MASTER CHART 
AUB   :  Abnormal uterine bleeding 
AUB(P)  :  Abnormal uterine bleeding with polyp 
AUB(F)  :  Abnormal uterine bleeding with fibroid                    
CAH   :  Complex atypical hyperplasia 
CHWA  :  Complex  hyperplasia without atypia 
DE   :  Disintegrating endometrium 
DEF.PE  :  Deficient Proliferative endometrium 
DPE   :  Disordered Proliferative endometrium 
DS   :  Deficient secretory    
DSSH  :  Deficient secretory with stromal  hemorrhage 
DUB   :  Dysfunctional uterine bleeding  
EACA  :  Endometrial adenocarcinoma. 
EP   :  Endometrial polyp 
ES   :  Early secretory endometrium 
IPE   : Irregular proliferation of endometrium 
IS   :  Irregular shedding 
LS   :  Late  secretory endometrium 
MS   : Mid  secretory endometrium 
PE   :  Proliferative endometrium  
PEWC  :  Proliferative endometrium with cystic change 
PEWD  :  Proliferative endometrium with disintegration 
SHWA  :  Simple hyperplasia without atypia 
SHWC  :  Simple hyperplasia with cystic change 
SHWD  :  Simple hyperplasia with disintegration 
SHWE  : Simple hyperplasia with chronic endometritis 
SHWP  :  Simple hyperplasia with polyp 
SHWS  :  Simple hyperplasia with squamous metaplasia 
 
 
